GO:0002016 regulation of blood volume by renin-angiotensin: Blood Pressure Homeostasis, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0002016 describes how the renin-angiotensin system (RAS) controls the rate of fluid intake and output into the blood, thereby regulating blood volume.
• The cascade begins with renin release from juxtaglomerular cells, which is now known to be mechanically regulated by renal PIEZO2.
• Angiotensin II is the principal effector, driving vasoconstriction, aldosterone release, sodium retention and thirst to restore circulating volume.
• Dysregulation of this process underlies hypertension, heart failure, chronic kidney disease and nonatherosclerotic renovascular hypertension.
• The system is modulated by cyclic nucleotides and phosphodiesterases, offering pharmacological entry points.
• CRISPR knockout, knock-in and overexpression models of RAS genes allow causal dissection of blood volume regulation in vivo and in vitro.
Description
Regulation of blood volume by renin-angiotensin (GO:0002016) is the biological process through which the renin-angiotensin system (RAS) governs the rate of fluid intake and output into the blood. This process is central to circulatory homeostasis because blood volume directly determines venous return, cardiac output and arterial pressure. The RAS is a ubiquitous endocrine and paracrine system that couples renal sodium handling, vascular tone and thirst behaviour into a single volume-regulatory circuit. Understanding GO:0002016 is therefore essential for researchers studying hypertension, heart failure, renal disease and electrolyte disorders. Recent work has identified mechanosensitive and cyclic-nucleotide-dependent inputs that fine-tune renin secretion, expanding the classical view of this pathway. Because the process integrates multiple organs and cell types, it is a prime target for CRISPR-based functional genomics.
regulation of blood volume by renin-angiotensin At A Glance
| GO ID | GO:0002016 |
|---|---|
| GO term | regulation of blood volume by renin-angiotensin |
| Ontology | biological_process |
| Synonym | renin-angiotensin control of body fluid levels; renin-angiotensin regulation of blood volume |
| Definition | The process in which the renin-angiotensin system controls the rate of fluid intake and output into the blood. |
| Major function | Maintenance of circulating blood volume and arterial pressure through renin, angiotensin II, aldosterone and thirst |
| Key organs | Kidney (juxtaglomerular cells), adrenal cortex, vasculature, brain |
| Key trigger | Reduced renal perfusion pressure, low distal sodium, sympathetic beta-1 stimulation, and mechanical cues via PIEZO2 |
| Effector hormone | Angiotensin II, with aldosterone as the major downstream volume-retaining hormone |
What Is GO:0002016?
In our own words, GO:0002016 refers to the set of physiological actions by which the renin-angiotensin system adjusts how much fluid enters and leaves the bloodstream, thereby keeping blood volume within a functional range. It encompasses renin release, angiotensin peptide generation, aldosterone-driven sodium and water retention, vascular responses and thirst, all of which converge on the rate of fluid intake and output into the blood.
Why Is regulation of blood volume by renin-angiotensin Important in Cell Biology?
GO:0002016 is important because it is the principal long-term determinant of blood pressure and extracellular fluid volume, and its dysregulation is causally implicated in hypertension, heart failure, chronic kidney disease and renovascular disease. Pharmacological blockade of the RAS is among the most widely used therapeutic strategies in cardiovascular medicine, underscoring the translational value of understanding this process at molecular resolution.
• Sets long-term blood pressure by matching renal sodium and water excretion to intake.
• Drives aldosterone secretion, which promotes sodium retention and potassium excretion.
• Stimulates thirst and salt appetite, linking behaviour to volume status.
• Mediates vasoconstriction that maintains perfusion pressure during hypovolaemia.
• Contributes to cardiac and vascular remodelling when chronically activated.
• Is a major drug target (ACE inhibitors, ARBs, renin inhibitors, MR antagonists).
• Is implicated in nonatherosclerotic renovascular hypertension.
• Is modulated by cyclic nucleotides and phosphodiesterases, revealing new regulatory nodes.
• Renal PIEZO2 provides a mechanotransduction input to renin release.
• Provides a tractable system for CRISPR functional genomics of blood pressure.
What Happens During regulation of blood volume by renin-angiotensin?
Sensing of volume status and renin release
In simple terms: The kidney senses when blood volume or pressure is low and releases renin as the first signal.
Juxtaglomerular cells in the afferent arteriole release renin in response to reduced renal perfusion pressure, decreased distal tubular sodium chloride delivery, and sympathetic beta-1 adrenergic stimulation. Recent work shows that the mechanosensitive ion channel PIEZO2 in the kidney is an essential regulator of renin release, linking physical stretch to the hormonal cascade. Cyclic nucleotides and phosphodiesterases further modulate renin secretion, providing additional layers of control.
Angiotensin peptide generation
In simple terms: Renin starts a chain reaction that produces the active hormone angiotensin II.
Renin cleaves angiotensinogen to angiotensin I, which is converted by angiotensin-converting enzyme (ACE) to angiotensin II. Angiotensin II is the principal effector of GO:0002016, acting on AT1 receptors in the vasculature, adrenal cortex, kidney and brain.
Aldosterone-mediated sodium and water retention
In simple terms: Angiotensin II tells the adrenal gland to release aldosterone, which makes the kidney keep salt and water.
Angiotensin II stimulates aldosterone secretion from the adrenal zona glomerulosa; aldosterone acts on the distal nephron to increase sodium reabsorption and potassium secretion, expanding extracellular fluid volume. This is the major mechanism by which the RAS increases blood volume over hours to days.
Vascular and neural effects
In simple terms: Angiotensin II tightens blood vessels and triggers thirst, both of which help restore blood volume.
Angiotensin II causes vasoconstriction, increases sympathetic outflow, and stimulates thirst and salt appetite through central AT1 receptors. These rapid responses complement the slower renal actions and together regulate the rate of fluid intake and output into the blood.
Feedback and counter-regulation
In simple terms: Once volume is restored, the system shuts itself off to prevent overshoot.
Increased blood volume and pressure suppress renin release via baroreceptor and macula densa feedback, while angiotensin II negatively feeds back on renin secretion. Cyclic nucleotide signalling and phosphodiesterases modulate these feedback loops, and PIEZO2-dependent mechanotransduction contributes to the set point of renin release.
Key Genes Involved in GO:0002016 regulation of blood volume by renin-angiotensin
The following genes and proteins are the principal molecular players in GO:0002016, based on the cited literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| REN | Encodes renin, the rate-limiting enzyme that initiates the cascade | Target for renin inhibitors; KO models define baseline renin activity |
| AGT | Encodes angiotensinogen, the substrate for renin | Genetic variants linked to blood pressure; substrate for kinetic studies |
| ACE | Converts angiotensin I to angiotensin II | Target of ACE inhibitors; key node in volume regulation |
| ACE2 | Counter-regulatory enzyme generating angiotensin-(1-7) | Balances RAS activity; relevant to cardiovascular protection |
| AGTR1 | AT1 receptor mediating angiotensin II effects | Target of ARBs; central to vasoconstriction and aldosterone release |
| AGTR2 | AT2 receptor with counter-regulatory actions | Modulates growth and apoptosis in cardiovascular tissue |
| CYP11B2 | Aldosterone synthase in adrenal zona glomerulosa | Determines aldosterone output; target for MR antagonist research |
| NR3C2 | Mineralocorticoid receptor mediating aldosterone effects | Target of spironolactone and eplerenone |
| SCNN1A | Epithelial sodium channel subunit in distal nephron | Effector of sodium retention; Liddle syndrome gene |
| PIEZO2 | Mechanosensitive channel regulating renin release | Newly identified node linking mechanics to RAS |
| ADRB1 | Beta-1 adrenergic receptor stimulating renin release | Target of beta-blockers affecting renin secretion |
| PDE3A | Phosphodiesterase modulating cyclic nucleotide levels in renin cells | Entry point for cAMP/PDE-based modulation of RAS |
| PDE4 | Phosphodiesterase family regulating cAMP in RAS tissues | Potential pharmacological target in volume disorders |
| NOS1 | Neuronal nitric oxide synthase influencing macula densa signalling | Modulates renin release via NO-cGMP pathway |
| COX2 | Cyclooxygenase-2 supporting renin secretion in some states | Relevant to NSAID effects on blood pressure |
| AQP2 | Aquaporin-2 mediating water reabsorption downstream of aldosterone | Marker of volume retention in collecting duct |
| SLC12A3 | Thiazide-sensitive NaCl cotransporter in distal tubule | Effector of sodium handling; Gitelman syndrome gene |
How Is regulation of blood volume by renin-angiotensin Regulated?
GO:0002016 is regulated at multiple levels. Renin release is controlled by renal baroreceptors, macula densa sodium sensing, sympathetic beta-1 signalling, and mechanotransduction via PIEZO2. Cyclic nucleotides and phosphodiesterases modulate renin secretion and downstream RAS activity, providing intracellular regulatory input. Angiotensin II exerts negative feedback on renin release, while aldosterone and mineralocorticoid receptor signalling adjust distal nephron sodium transport. Dietary salt intake strongly influences the set point of the system, with high salt suppressing and low salt activating the RAS.
regulation of blood volume by renin-angiotensin and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| REN | Renovascular hypertension, low-renin states | Renal PIEZO2 or REN knockout mouse; renin reporter cells |
| AGT | Essential hypertension, preeclampsia | AGT knock-in mice with human variants; overexpression cell lines |
| ACE | Hypertension, heart failure, diabetic nephropathy | ACE knockout and point-mutation models; ACE inhibitor studies |
| AGTR1 | Hypertension, cardiac hypertrophy | AT1 receptor knockout and knock-in mice; ARB response assays |
| CYP11B2 | Primary aldosteronism, adrenal hyperplasia | Adrenal cell lines with CYP11B2 overexpression or KO |
Hypertension and salt sensitivity
Excessive RAS activity raises blood volume and vascular tone, contributing to essential and salt-sensitive hypertension. High dietary salt intake modulates the pathogenesis and treatment response of hypertension, and RAS blockade remains a cornerstone of therapy.
Heart failure and cardiac remodelling
Chronic activation of GO:0002016 promotes sodium and water retention and adverse cardiac remodelling, which are hallmarks of heart failure. Inhibition of the RAS improves outcomes in heart failure, validating the pathway as a therapeutic target.
Chronic kidney disease and renovascular hypertension
Renal artery stenosis activates renin release and drives nonatherosclerotic renovascular hypertension. Dysregulated RAS activity also contributes to progressive kidney injury and proteinuria.
Electrolyte and adrenal disorders
Primary aldosteronism and related adrenal disorders increase aldosterone synthase activity and enhance sodium retention, illustrating how dysregulation of GO:0002016 causes volume expansion and hypokalaemia.
From regulation of blood volume by renin-angiotensin-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of REN abolish angiotensin II generation? | REN knockout mouse or isogenic REN KO cell line |
| Does a human AGT variant alter angiotensinogen cleavage? | AGT point-mutation knock-in cell model |
| Does PIEZO2 mediate mechanically induced renin release? | PIEZO2 knockout and tagged knock-in in renin-expressing cells |
| Does overexpression of CYP11B2 increase aldosterone output? | CYP11B2 overexpression adrenal cell line |
| Does AT1 receptor signalling drive sodium retention? | AGTR1 knockout and knock-in models with aldosterone readouts |
| Can CRISPR library screening identify new RAS regulators? | Genome-wide CRISPR knockout screen in renin reporter cells |
How to Study the regulation of blood volume by renin-angiotensin Process
| Method | What It Measures | Typical Application |
|---|---|---|
| CRISPR knockout | Loss-of-function effect on blood volume regulation | Testing REN, AGT, ACE, AGTR1 necessity |
| CRISPR knock-in | Effect of specific human variants | AGT or AGTR1 point-mutation models |
| RNA-seq | Transcriptional changes in RAS tissues | Renin cell and adrenal responses to salt |
| Proteomics | Protein abundance of RAS components | Quantifying renin, ACE, angiotensinogen |
| Plasma renin activity assay | Enzymatic activity of renin | Diagnosing renovascular hypertension |
| Aldosterone measurement | Adrenal output downstream of angiotensin II | Primary aldosteronism and heart failure studies |
| Blood pressure telemetry | In vivo haemodynamic effect | Assessing volume regulation in KO mice |
| Reporter imaging | Real-time renin release and receptor localization | PIEZO2 and AT1 dynamics |
Genetic and genomic approaches
CRISPR knockout, knock-in and overexpression models allow causal testing of RAS genes in blood volume regulation. Genome-wide CRISPR screens can nominate novel regulators of renin secretion and angiotensin signalling.
Transcriptomic and proteomic profiling
RNA-seq of renin-expressing cells and RAS target tissues reveals transcriptional responses to volume challenge, while proteomics can quantify renin, angiotensinogen and ACE abundance.
Physiological and hormonal assays
Plasma renin activity, angiotensin II and aldosterone measurements, together with blood pressure and sodium balance studies, directly assess GO:0002016 output.
Imaging and reporter systems
Renin reporter mice and fluorescent tagging of PIEZO2 or AT1 receptors enable real-time visualization of renin release and receptor localization.
How CRISPR Can Be Used to Study GO:0002016 regulation of blood volume by renin-angiotensin
Knockout
CRISPR knockout of REN, AGT, ACE or AGTR1 in cell lines and mice establishes which components are required for blood volume regulation and provides isogenic controls for downstream assays.
Point Mutation
Point-mutation knock-in of human AGT or AGTR1 variants allows researchers to test whether specific alleles alter angiotensinogen cleavage or receptor signalling in a controlled genetic background.
Knock-in
Tagged knock-in of PIEZO2 or REN with fluorescent or epitope tags enables visualization and purification of the endogenous proteins that regulate renin release.
Overexpression
Overexpression of CYP11B2, AGTR1 or ACE in adrenal or vascular cell lines models gain-of-function states associated with hypertension and volume expansion.
How EDITGENE Supports regulation of blood volume by renin-angiotensin Research
Researchers studying regulation of blood volume by renin-angiotensin-related genes often need to determine whether a candidate gene is causally involved in renin release, angiotensin signalling or sodium retention, and CRISPR-based models provide the most direct way to test this.
Contact EDITGENE today to design your custom CRISPR model for regulation of blood volume by renin-angiotensin research.
Frequently Asked Questions About regulation of blood volume by renin-angiotensin
What is GO:0002016?
GO:0002016 is the biological process in which the renin-angiotensin system controls the rate of fluid intake and output into the blood, thereby regulating blood volume.
What genes are involved in regulation of blood volume by renin-angiotensin?
Key genes include REN, AGT, ACE, ACE2, AGTR1, AGTR2, CYP11B2, NR3C2 and PIEZO2.
How does the renin-angiotensin system regulate blood volume?
Renin release triggers angiotensin II production, which drives vasoconstriction, aldosterone secretion, sodium retention and thirst to restore circulating volume.
What triggers renin release?
Reduced renal perfusion pressure, low distal sodium delivery, sympathetic beta-1 stimulation and mechanical cues via PIEZO2 trigger renin release.
What is the role of aldosterone in blood volume regulation?
Aldosterone increases sodium reabsorption and potassium secretion in the distal nephron, expanding extracellular fluid volume.
How is the renin-angiotensin system regulated by cyclic nucleotides?
Cyclic nucleotides and phosphodiesterases modulate renin secretion and downstream RAS activity, providing intracellular control of the pathway.
What diseases are linked to dysregulated renin-angiotensin blood volume control?
Hypertension, heart failure, chronic kidney disease, renovascular hypertension and primary aldosteronism are linked to RAS dysregulation.
How can CRISPR be used to study GO:0002016?
CRISPR knockout, knock-in, point mutation and overexpression models allow causal testing of RAS genes in renin release and sodium retention.
What is the role of PIEZO2 in renin regulation?
Renal PIEZO2 is a mechanosensitive channel that is essential for renin release, linking mechanical stretch to the RAS.
Why is salt intake important for renin-angiotensin blood volume regulation?
Dietary salt intake strongly influences the set point of the RAS, with high salt suppressing and low salt activating the system, affecting hypertension pathogenesis and treatment.
Conclusion
GO:0002016, regulation of blood volume by renin-angiotensin, is a central physiological process that integrates renal, adrenal, vascular and neural signals to maintain circulating volume. Its dysregulation underlies major cardiovascular and renal diseases, making it a high-value target for both pharmacological and CRISPR-based research. Advances in mechanotransduction and cyclic nucleotide biology continue to refine our understanding of how this pathway is controlled.
References
- 1. Triebel H et al.. 2024. The renin angiotensin aldosterone system.. Pflugers Arch 476(5):705-713 PMID: 38233636
- 2. Patel S et al.. 2017. Renin-angiotensin-aldosterone (RAAS): The ubiquitous system for homeostasis and pathologies.. Biomed Pharmacother 94:317-325 PMID: 28772209
- 3. Rust P et al.. 2017. Impact of Salt Intake on the Pathogenesis and Treatment of Hypertension.. Adv Exp Med Biol 956:61-84 PMID: 27757935
- 4. Gambaryan S et al.. 2023. Regulation of the renin-angiotensin-aldosterone system by cyclic nucleotides and phosphodiesterases.. Front Endocrinol (Lausanne) 14:1239492 PMID: 37674612
- 5. Kaur J et al.. 2026. Physiology, Renin Angiotensin System.. PMID: 29261862
- 6. Dalman J et al.. 2023. Nonatherosclerotic Renovascular Hypertension.. Surg Clin North Am 103(4):733-743 PMID: 37455034
- 7. Hill RZ et al.. 2026. Renal PIEZO2 is an essential regulator of renin.. Cell 189(1):161-178.e22 PMID: 41349545
- 8. Hall JE. 1991. Control of blood pressure by the renin-angiotensin-aldosterone system.. Clin Cardiol 14(8 Suppl 4):IV6-21; discussion IV51-5 PMID: 1893644
